Aiweide raises early VC round for its organ-on-a-chip tech
What's the deal? Jiangsu Aiweide BiotechnologyDealroom has a profile for this one. Try Dealroom → has closed an early-stage venture round to advance its organ-on-a-chip technology. The round was led by the Nanjing Jiangbei New Area New Quality Research and Production Venture Capital Fund.
Who else joined? Backers include the Nanjing Zijin Biomedical Industry Investment Fund, the Nanjing University Science and Technology Achievement Transformation Angel Fund, the Nanjing Xingong Biomedical Proof of Concept Venture Capital Fund, Shanghai Bangmei FuchuangDealroom has a profile for this one. Try Dealroom →, and Shanghai Wanfeng New Material TechnologyDealroom has a profile for this one. Try Dealroom →. The mix pairs government-linked funds with industrial capital.
What's the endgame? Aiweide develops medical devices and instruments built on human organ-on-a-chip technology. Its lead product is a tumour organ-on-a-chip system serving drug discovery and precision medicine.
Why now? The round announced in August 2026 draws heavily on Nanjing-based public funds tied to biomedical research and technology transfer, signalling regional support for the sector.
The signal: The concentration of proof-of-concept and industry investment funds around Aiweide points to growing appetite for organ-on-a-chip platforms as tools for drug development and personalised treatment.
Image credit: Generated with Gemini
